Lucentis Sales Data
| Rank 29 | Current sales rank, all U.S. Pharmaceuticals. |
Last updated: May 2013 (updated quarterly).
The following data shows Lucentis U.S. retail sales in Q1 2013 compared to previous quarters.
| Date Range | Sales Rank | Sales ($000) | Units (000) | ||
|---|---|---|---|---|---|
| Q1 2013 | 29 ( 1) |
$415,406 | 4.92% | 242 | 6.14% |
| Q4 2012 | 30 (1) |
$395,931 | 3.63% | 228 | 7.04% |
| Q3 2012 | 31 (6) |
$382,048 | -1.88% | 213 |  |
| Q2 2012 | 37 ( 2) |
$389,387 | -4.92% | 213 | -4.91% |
| Q1 2012 | 35 (5) |
$409,547 | -6.89% | 224 | -5.88% |
| Q4 2011 | 30 (2) |
$439,867 | 2.44% | 238 | 2.59% |
| Q3 2011 | 28 (2) |
$429,393 | 1.13% | 232 | 0.87% |
| Q2 2011 | 30 (3) |
$424,611 | 0.95% | 230 | 1.32% |
| Q1 2011 | 33 | $420,635 | |
227 | |
* Units refer to the number of packages sold.
Source: IMS Health (Midas). Please review our terms of use and attribution guidelines. Copyright - All rights reserved. Unauthorized use and/or duplication of this material without express written permission is strictly prohibited.
See Also
Related News
| Date | Article |
|---|---|
| August 10, 2012 | FDA Gives Nod to Lucentis for Diabetic Eye Disease |
| August 10, 2012 | Lucentis Approved for Diabetic Macular Edema |
| September 12, 2011 | Eye Antibiotics Can Cause Drug-Resistant Bacteria: Study |
| January 7, 2011 | Novartis International AG (CH) - Novartis Gains New Indication for Lucentis in EU for Vision Loss due to Diabetic Macular Edema, a Leading Cause of Blindness |
